Targeted protein degradation – New modalities and design technologies

In the attempt of treating all human diseases, the realization of a cohort of targets being deemed as ‘undruggable’ is a growing market in therapeutics. With more and more researchers focusing on these targets, it has unveiled the opportunity to expand our knowledge of these larger and more complex proteins that fail to fit into conventional drug design strategies.

‘Out-of-the-box’ approaches are driving pharmaceutical developments forward with encouraging results. Join Dr. Bernhard Fasching, of Monte Rosa Therapeutics and Dr, Benedict Cross, of PhoreMost Therapeutics, as they share the promising new modalities in drug discovery, unveiling strategies and technologies aimed at targeting previously ‘undruggable’ diseases.

This webinar offers valuable insights for both seasoned researchers and newcomers, enhancing their understanding of the latest advancements in drug discovery, including topics of molecular glue degraders and editing the proteome.

Key learning objectives

• Discover the latest advancements in drug discovery
• Gain insight into molecular glue degraders (features and origins)
• Learn more about targeted protein degradation (editing the proteome)

Who should attend

Researchers in drug discovery, researchers working with ‘undruggable targets’.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.